Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.
Also called NCT02145546
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 600 participants
- Registry
-
NCT02145546
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02145546. Randomized; no masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation
- Acronym
- ADA-PAF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Amiodarone
- Intervention (Drug)
- Propafenone
- Intervention (Drug)
- Sotalol
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator
- Medtronic (Shanghai) Management Co. Ltd.
- Collaborator
- Beijing CTSmed Co. Ltd
Record details
- Record id
cardio:ct-nct02145546- Content hash
f7cd351a00b473fd1e3eadf3da9840cd482ca4980103c420f0995d4c514c9f93